-
Je něco špatně v tomto záznamu ?
Multiplex biomarker approach to cardiovascular diseases
M. Adamcova, F. Šimko,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, přehledy
NLK
Free Medical Journals
od 1980
PubMed Central
od 2009 do Před 1 rokem
Europe PubMed Central
od 2009 do Před 1 rokem
ProQuest Central
od 2005-01-01 do Před 1 rokem
Open Access Digital Library
od 2009-01-01
Health & Medicine (ProQuest)
od 2005-01-01 do Před 1 rokem
PubMed
29645001
DOI
10.1038/aps.2018.29
Knihovny.cz E-zdroje
- MeSH
- biologické markery analýza MeSH
- ELISA MeSH
- kardiovaskulární nemoci diagnóza farmakoterapie MeSH
- lidé MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Personalized medicine is partly based on biomarker-guided diagnostics, therapy and prognosis, which is becoming an unavoidable concept in modern cardiology. However, the clinical significance of single biomarker studies is rather limited. A promising novel approach involves combining multiple markers into a multiplex panel, which could refine the management of a particular patient with cardiovascular pathology. Two principally different assay formats have been developed to facilitate simultaneous quantification of multiple antigens: planar array assays and microbead assays. These approaches may help to better evaluate the complexity and dynamic nature of pathologic processes and offer substantial cost and sample savings compared with traditional enzyme-linked immunosorbent assay (ELISA) measurements. However, a multiplex multimarker approach cannot become a generally disseminated method until analytical problems are solved and further studies confirming improved clinical outcomes are accomplished. These drawbacks underlie the fact that a limited number of systematic studies are available regarding the use of a multiplex biomarker approach in cardiovascular medicine to date. Our perspective underscores the significant potential of the use of the multiplex approach in a wider conceptual framework under the close cooperation of clinical and experimental cardiologists, pathophysiologists and biochemists so that the personalized approach based on standardized multimarker testing may improve the management of various cardiovascular pathologies and become a ubiquitous partner of population-derived evidence-based medicine.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19000808
- 003
- CZ-PrNML
- 005
- 20190111144817.0
- 007
- ta
- 008
- 190107s2018 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/aps.2018.29 $2 doi
- 035 __
- $a (PubMed)29645001
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Adamcova, Michaela $u Department of Physiology, Faculty of Medicine in Hradec Kralove, Charles University in Prague, Hradec Kralove, Czech Republic. adamcova@lfhk.cuni.cz.
- 245 10
- $a Multiplex biomarker approach to cardiovascular diseases / $c M. Adamcova, F. Šimko,
- 520 9_
- $a Personalized medicine is partly based on biomarker-guided diagnostics, therapy and prognosis, which is becoming an unavoidable concept in modern cardiology. However, the clinical significance of single biomarker studies is rather limited. A promising novel approach involves combining multiple markers into a multiplex panel, which could refine the management of a particular patient with cardiovascular pathology. Two principally different assay formats have been developed to facilitate simultaneous quantification of multiple antigens: planar array assays and microbead assays. These approaches may help to better evaluate the complexity and dynamic nature of pathologic processes and offer substantial cost and sample savings compared with traditional enzyme-linked immunosorbent assay (ELISA) measurements. However, a multiplex multimarker approach cannot become a generally disseminated method until analytical problems are solved and further studies confirming improved clinical outcomes are accomplished. These drawbacks underlie the fact that a limited number of systematic studies are available regarding the use of a multiplex biomarker approach in cardiovascular medicine to date. Our perspective underscores the significant potential of the use of the multiplex approach in a wider conceptual framework under the close cooperation of clinical and experimental cardiologists, pathophysiologists and biochemists so that the personalized approach based on standardized multimarker testing may improve the management of various cardiovascular pathologies and become a ubiquitous partner of population-derived evidence-based medicine.
- 650 _2
- $a biologické markery $x analýza $7 D015415
- 650 _2
- $a kardiovaskulární nemoci $x diagnóza $x farmakoterapie $7 D002318
- 650 _2
- $a ELISA $7 D004797
- 650 _2
- $a lidé $7 D006801
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Šimko, Fedor $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic. Third Department of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic. Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovak Republic.
- 773 0_
- $w MED00193644 $t Acta pharmacologica Sinica $x 1745-7254 $g Roč. 39, č. 7 (2018), s. 1068-1072
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29645001 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190107 $b ABA008
- 991 __
- $a 20190111145022 $b ABA008
- 999 __
- $a ok $b bmc $g 1363928 $s 1038931
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 39 $c 7 $d 1068-1072 $e 20180412 $i 1745-7254 $m Acta pharmacologica Sinica $n Acta Pharmacol Sin $x MED00193644
- LZP __
- $a Pubmed-20190107